Litigation

Blue Cross Blue Shield Association plaintiffs v. Celgene Corporation et al.

Auto-generating section 1 of 5: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Court: U.S. District Court for the District of New Jersey

Patents at issue (10)

Plaintiffs (1)

π Blue Cross Blue Shield Association plaintiffs

Defendants (2)

Summary

Antitrust action by Blue Cross Blue Shield Association plaintiffs against Celgene/BMS concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 7968569-blue-cross-blue-shield-association-plaintiffs-v-celgene-bms · edit in Admin

Further reading

§ 285 attorney-fee shifting in practice
§ 285 isn't a guaranteed remedy. It's a high-effort, high-evidence tool that pays off occasionally and dramatically — turning a $3M defense expense into a $3M plaintiff bill.
The first 30 days after a patent infringement complaint
Most defendants spend the first 30 days reacting. The defendants who do well spend it sequencing — because every move you make in month one shapes the budget, leverage, and exit options for the next two years.
Markman v. Westview Instruments, Inc. (1996)
Claim construction is exclusively the court's job. The Markman hearing is the most consequential single ruling in nearly every patent case — and a defendant's best chance to end the litigation before trial.
What is a patent?
A patent is a deal between an inventor and the government — a 20-year monopoly in exchange for public disclosure. Most patents that get litigated would not survive serious scrutiny.
How to read a patent claim chart
The claim chart is where the plaintiff's case actually lives. The complaint is a pitch deck; the chart is the homework — and most patent troll homework doesn't survive a careful read.

All resources →